Targeted Therapies for Advanced Renal Cell Carcinoma: New Standards of Care

The Center for Biomedical Continuing Education
Last Modified: February 13, 2009

Share article

Conference Dates: February 26, 2009
Conference Location: Orlando, FL

Sponsoring Group: The Center for Biomedical Continuing Education

Conference Web Page

Topics Covered: renal cell carcinoma, gene mutations, cellular signaling defects, metastasectomy, cytoreductive nephrectomy

Conference Objectives:

  1. Describe common gene mutations and cellular signaling defects that are characteristics of RCC.
  2. Describe prognostic and predictive factors that may be useful in determining optimal care for patients with RCC.
  3. Describe clinical considerations in the use of metastasectomy and cytoreductive nephrectomy followed by systematic therapy for patients with mRCC.
  4. Describe recent data regarding the safety and efficacy of novel agents targeting cell growth pathways for the treatment of RCC.
  5. Discuss recent clinical trials investigating the safety and efficacy of targeted agents that impact the vascular and endothelial growth factor-signaling pathway for the treatment of RCC.

Who Should Attend: medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, physicial assistants and other healthcare professionals interested in the treatment and care of patients with RCC


Continuing Education: Yes

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More